Prescription Drug Search

Strengths available for Efavirenz :

Efavirenz 200mg
Efavirenz 600mg

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about MyGlobalPharmacy.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Efavirenz:

  • Anguilla
  • Antigua and Barbuda
  • Austria
  • Azerbaijan
  • Bahrain
  • Barbados
  • Belgium
  • Belize
  • Cayman Islands
  • China
  • Ecuador
  • Egypt
  • Germany
  • Guadeloupe
  • India
  • Iraq
  • Japan
  • Korea, South
  • Kuwait
  • Lebanon
  • Lithuania
  • Luxembourg
  • Mauritius
  • Moldova, Republic of
  • New Zealand
  • Norway
  • Peru
  • Russian Federation
  • Saint Lucia
  • Singapore
  • South Africa
  • Sri Lanka
  • Trinidad and Tobago
  • Turkey
  • Ukraine
  • United Arab Emirates
  • United Kingdom, UK
  • United States, US
  • Uzbekistan
  • Venezuela
View All Countries

Latest news releases on Efavirenz:

FDA Approves New Labeling for ISENTRESS(R) (raltegravir) to Include 1...  - CNBC

Long-term efficacy of ISENTRESS (raltegravir) in treatment-naive adult patients with HIV-1 through three years In the STARTMRK trial, the regimen containing ISENTRESS was as effective as the regimen containing efavirenz at reducing HIV-1 viral load to ...

Merck Says FDA Approved Labeling Update For ISENTRESS - Quick Facts - RTT News

(RTTNews) - Merck (MRK: News ) said the FDA approved a labeling update for ISENTRESS (raltegravir) Film-coated Tablets to include 156-week data from the STARTMRK study with ISENTRESS in combination therapy compared to efavirenz in combination therapy in ...

Walt Disney and 2 Dow 30 Stocks Making Waves - Wall St. Cheat Sheet

Merck & Co. Inc. (NYSE:MRK) has been granted FDA approval for a labeling update for Isentress Film-coated Tablets, which include 156 weeks of data from the StartMRK evaluation with Isentress, in combination therapy compared to efavirenz in combination ...

FDA ADAC recommends approval of Quad for HIV-1 infection - News-Medical.Net

The Quad NDA is supported by the positive results from two pivotal Phase 3 studies in which Quad met its primary objective of non-inferiority as compared to Atripla ® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg ...

UGANDA: Rising ARV resistance threatens HIV fight - IRIN

Most patients had resistance to a class of ARVs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which include commonly used medications such as nevirapine and efavirenz. The report revealed that poor treatment adherence to ARVs ...

FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV - Yahoo Finance

The Quad NDA is supported by the positive results from two pivotal Phase 3 studies in which Quad met its primary objective of non-inferiority as compared to Atripla ® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg ...

FDA Review Positive on Quad Pill for HIV - MedPage Today

If eventually approved, the quad pill would be the third single-pill, once-daily complete regimen for HIV, along with Atripla (efavirenz, emtricitabine, and tenofovir) and Complera (rilpivirine, emtricitabine, and tenofovir). All four drugs in ...

Tanzania Pharmaceuticals and Healthcare Report Q3 2012 - new market research report - Transworld News

Key Trends And Developments • In positive news for the Tanzanian population, the commercial production of country's first locally manufactured ARV drugs, including a first-line ARV, efavirenz, are due to begin. The manufacturing plant, in the northern ...

HIV Treatment Study in Patients with Cryptococcal Meningitis Ends Enrollment Early - Healthcanal.com

Antiretroviral therapy included an efavirenz-based regimen in accordance with national treatment guidelines, The study was slated to end in June 2015. Participants are being notified of the study’s developments and will continue to be followed by study staff.

Customer Service
1-866-799-3435 (Use Discount Code 10781) | Contact Form
Copyright © 2012 MyGlobalPharmacy.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK